Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

11 trials with published results (7%)

Research Maturity

136 completed trials (81% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 167 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

2%

3 trials in Phase 3/4

Results Transparency

8%

11 of 136 completed with results

Key Signals

11 with results100% success

Data Visualizations

Phase Distribution

167Total
Not Applicable (9)
Early P 1 (3)
P 1 (152)
P 3 (1)
P 4 (2)

Trial Status

Completed136
Unknown26
Not Yet Recruiting2
Withdrawn2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 136 completed trials

Clinical Trials (167)

Showing 20 of 20 trials
NCT06987773Phase 1CompletedPrimary

Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions

NCT07345130Phase 1CompletedPrimary

A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions

NCT07393022Phase 1Completed

Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects

NCT03340753Phase 1CompletedPrimary

Bioavailability of KBP-5074 Tablet vs Capsule Formulations

NCT07096869Phase 1RecruitingPrimary

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

NCT06655194Phase 1CompletedPrimary

A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants

NCT06830954Phase 1Not Yet RecruitingPrimary

Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants

NCT02206295Phase 1CompletedPrimary

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

NCT06778304Phase 1CompletedPrimary

Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30

NCT06758531Not ApplicableNot Yet Recruiting

Coffee Bioequivalence Trial

NCT05014490Phase 1CompletedPrimary

Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers

NCT06563856Phase 1Completed

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

NCT06331715Phase 4CompletedPrimary

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

NCT04268472Not ApplicableCompletedPrimary

Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

NCT06497049Phase 1Completed

Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.

NCT05883124Phase 1CompletedPrimary

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

NCT06164431Phase 1CompletedPrimary

Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273

NCT06213610Phase 1UnknownPrimary

Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions

NCT05642845Phase 1CompletedPrimary

Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions

NCT05685277Phase 1CompletedPrimary

Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions

Scroll to load more

Research Network

Activity Timeline